

RECEIVED

APR 2 4 2007

Approved for use through 10/31/2002. OME 665 1-003h

U.S. Petent and Trademark Office: U.S. DEPARTMENT OF COMMERCE/20

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO 10/0050,376 **Application Number** INFORMATION DISCLOSURE 01/16/2002 Filing Date STATEMENT BY APPLICANT Uwe Joerg RIES First Named Inventor -1614 1602 G Art Unit (use as many sheets as necessary) K. Anderson Examiner Name Attorney Docket Number 5/1312 of 1 Sheet

U.S. PATENT DOCUMENTS					
Examiner Initials		Document Number Number - Kind Code ² (if known	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- US- US- US- US- US- US- US- US- US-			
	-	US- US- US- US- US- US- US- US-			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (if Innown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Whare Relevant Passages or Relevant Figures Appear	T ⁶	
R		WO 01 10823 WO 00 71508	02/15/2001 11/30/2000	BI Pharma KG COR Therapeutics			
RX		WO 00 71512	11/30/2000	COR Therapeutics			
	.						

Examiner Date ndlison Considered Signature

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (02-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

bstitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Co	mplet if Known	
Application Number	10/050,376	
Filing Date	January 16, 2002	TO SI
First Named Inventor	Ries, U. et al	
Art Unit	1614-1626	10 2
Examiner Name	R. Amprison	1200 C
Attorney Docket Number	5/1312	777
		1000
DOCUMENTS		¥200
	1	7/7//-

		 	U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (N known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-	 		
		Us-			
		US-			
		UŞ-			
		US-			
-		US-			
		US-			

	,	FORE	IGN PATENT DOCU	JMENTS		,
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ -Number ⁴ -Kind Cade ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T³
YCA		WO 96/40100	12-19-1996	3-Dimensional Pharm.		
Po		WO 00/56707	09-28-2000	Sepracor, Inc.	·	
PS		WO 02/04403 A1	01-17-2002	Boehringer Ingelheim		
100		GB 2007663	05-23-1979	VEB Arzneimittelwerk		
PA		EP 0654465	05-24-1995	CIBA-GEIGY AG		

Examiner Date Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible, ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1,14. This collection is estimated to take 2 hours to complete, Including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231,

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

>	E			•
1	6 2003 E User the Paperwork Reduction Act of 1995, no persons and		PTO/S6/08B (02-03 Approved for use through 04/30/2003. OMB 0651-003 t and Trademark Office; U.S. DEPARTMENT OF COMMERC of information unless it contains a valid OMB contribumber	រៅ E
TE	TRANSITUTE for form 1449/PTO		Compl te if Kn wn	1
		Application Number	10/050,376	
	INFORMATION DISCLOSURE	Filing Date	January 16, 2002 APP	TUR
	STATEMENT BY APPLICANT	First Named Inventor	Ries, U. et al	7 200
		Art Unit	1614 1626 CENTED	- 2003
	(Use as many sheets as necessary)	Examiner Name	R. Anderson	600/200
'	Sheet 2 of 2	Attorney Docket Number	5/1312	7 -300

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PA		LABES, D. and HAGEN, V. "Free-Wilson-Analyse der Hemmwirkung von 4-substituierten Benzamidinen gegenueber Thrombin, Plasmin und Trypsin" Pharmazie, 1979, 34(9):554-555	
Bb		TAMIZ, A.P. et al "A Convenient Procedure for the Syntheses of Nonsymmetrical Bivalent Selective Serotonin Reuptake Inhibitors Using Polymer-Supported Reagents" Bioorganic & Med. Chem. Ltrs, 2000, 10:2741-2743.	
RS		VALENTI, et al, "Cyclovinylogs of procainamide" Chemical Abstracts, 1983, 98(7):620	·
Ph		Database Crossfire Beilstein, Beilstein Instutue Zur Foerderung Der Chemischen Wissenschafter, Frankfurt AM Main, DE	
			-
·			
- Indiana - Indi			

Examiner	1	Date	1
Signature leen	malera	Considered	8/20/03
NEVALUATED LISTAL SECTION AND AND AND AND AND AND AND AND AND AN	and the state of the second control of the second		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.